Please ensure Javascript is enabled for purposes of website accessibility

Why Global Blood Therapeutics Surged 16.7% Higher in January

By Todd Campbell – Updated Apr 19, 2019 at 10:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors hope that its lead drug candidate can make it to the Food and Drug Administration for approval soon.

What happened

A presentation at the J.P. Morgan Healthcare Conference in early January kindled excitement that Global Blood Therapeutics (GBT 0.01%) could be on the cusp of launching a blockbuster drug for sickle cell disease, a painful genetic disorder affecting hundreds of thousands of people worldwide. Word that management intends to talk about its new drug's application options with the Food and Drug Administration soon sent shares rocketing 16.7% higher in January, according to S&P Global Market Intelligence

So what

Global Blood Therapeutics has just one drug in its clinical-stage pipeline: voxelotor, an oral, once-daily treatment for sickle cell disease (SCD). Voxelotor helps prevent red blood cells from forming into their misshapen "sickle" look by boosting the amount of oxygen in hemoglobin. 

Ascending stacks of oral tablets sit on top of $100 bills.


In December, data was unveiled by management showing that a 1,500 mg daily dose of voxelotor increased hemoglobin at the 24-week mark by at least 1 gram per deciliter in 65% of patients. That was significantly better than the 33% of patients seeing that improvement following a placebo.

The company also said that the FDA has agreed to an accelerated pathway that could allow voxelotor to reach the market more quickly. A meeting is planned with regulators by the end of this quarter to discuss voxelotor's potential, according to a presentation at the J.P. Morgan conference last month.

Check out the latest earnings call transcripts for companies we cover.  

Now what

If the meeting goes well and voxelotor does eventually get a green light, then it could mark a major advance in treating SCD patients. SCD can cause painful vaso-occlusive crises that land patients in the hospital. On average, a sickle cell patient's life span is 20 to 30 years shorter than a healthy person's, and the cost of care for these patients is roughly $200,000 per year. Because over 100,000 patients in the U.S. alone have SCD and there's an undeniable need for new treatment options, hope is high that voxelotor has blockbuster potential.

However, there's no guarantee that voxelotor crosses the finish line. Its clinical trials are evaluating its ability to boost hemoglobin and brain blood flow, and that's not the primary end point typically used to support approvals in this indication. In the past, the focus has been on reducing vaso-occlusive crises. There's also the risk that the market for SCD treatment will be disrupted by gene therapies in development that are designed to restore normal hemoglobin production in a one-and-done dose. If gene therapy is successful, it could significantly reduce voxelotor's peak sales opportunity. 


Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Global Blood Therapeutics Stock Quote
Global Blood Therapeutics
$68.49 (0.01%) $0.01
JPMorgan Chase Stock Quote
JPMorgan Chase
$110.39 (-1.24%) $-1.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.